ERBB2 and breast carcinoma: Recently, the TOUCH trial showed that in HR + HER2 positive early breast cancer (eBC), endocrine combination therapy with palbociclib and dual blockade can achieve pCR rates comparable to those of paclitaxel plus dual blockade [60].